You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriflupromazine
Accession NumberDB00508  (APRD00465)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem]
Structure
Thumb
Synonyms
10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine
2-(Trifluoromethyl)promazine
2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine
Fluopromazine
Triflupromazin
Triflupromazina
Triflupromazine
Triflupromazinum
External Identifiers
  • MC 4703
  • SKF 4648-A
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VesprinBristol Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Triflupromazine Hydrochloride
ThumbNot applicableDBSALT001039
Categories
UNIIRO16TQF95Y
CAS number146-54-3
WeightAverage: 352.417
Monoisotopic: 352.122103923
Chemical FormulaC18H19F3N2S
InChI KeyInChIKey=XSCGXQMFQXDFCW-UHFFFAOYSA-N
InChI
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
dimethyl({3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl})amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed mainly in the management of psychoses. Also used to control nausea and vomiting.
PharmacodynamicsTriflupromazine is a member of a class of drugs called phenthiazines, which are dopamine D1/D2 receptor antagonists. Phenothiazines are used to treat serious mental and emotional disorders, including schizophrenia and other psychotic disorders. It reduces anxiety, emotional withdrawal, hallucinations, disorganized thoughts, blunted mood, and suspiciousness. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system.
Mechanism of actionTriflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B).
Related Articles
AbsorptionAbsorption may be erratic and peak plasma concentrations show large interindividual differences.
Volume of distributionNot Available
Protein bindingVery high (90% or more).
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9839
Caco-2 permeable+0.7847
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8737
Renal organic cation transporterInhibitor0.6721
CYP450 2C9 substrateNon-substrate0.7813
CYP450 2D6 substrateSubstrate0.5115
CYP450 3A4 substrateSubstrate0.5822
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9141
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.8156
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6166
Ames testNon AMES toxic0.875
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.2485 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Inhibitor0.8433
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP5.54BIOBYTE (1995)
logS-5.3ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0018 mg/mLALOGPS
logP4.95ALOGPS
logP4.81ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.93 m3·mol-1ChemAxon
Polarizability35.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.91 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9121000000-0dfbd5aaf88b987dbe84View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AA05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Triflupromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with 7-Nitroindazole.
AcebutololTriflupromazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Triflupromazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Triflupromazine.
adipiplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Triflupromazine.
AgomelatineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Triflupromazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alfaxalone.
AlfentanilTriflupromazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triflupromazine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Triflupromazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Triflupromazine.
AlphacetylmethadolTriflupromazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triflupromazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triflupromazine.
AlprenololTriflupromazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Triflupromazine.
AmisulprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triflupromazine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Triflupromazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Triflupromazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amperozide.
AmphetamineTriflupromazine may decrease the stimulatory activities of Amphetamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Triflupromazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aripiprazole.
ArotinololTriflupromazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Triflupromazine.
ArtemetherThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Triflupromazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Triflupromazine.
AtenololTriflupromazine may increase the hypotensive activities of Atenolol.
AtovaquoneThe serum concentration of Triflupromazine can be increased when it is combined with Atovaquone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Triflupromazine.
AzaperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azaperone.
AzelastineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triflupromazine.
BaclofenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.
BefunololTriflupromazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzocaine.
BenzphetamineTriflupromazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Triflupromazine.
BetaxololTriflupromazine may increase the hypotensive activities of Betaxolol.
BevantololTriflupromazine may increase the hypotensive activities of Bevantolol.
BezitramideTriflupromazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololTriflupromazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Triflupromazine.
BopindololTriflupromazine may increase the hypotensive activities of Bopindolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Triflupromazine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
BrimonidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triflupromazine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Triflupromazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brotizolam.
BufuralolTriflupromazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triflupromazine.
BupranololTriflupromazine may increase the hypotensive activities of Bupranolol.
BuprenorphineTriflupromazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triflupromazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine.
ButacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butethal.
ButorphanolTriflupromazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triflupromazine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Triflupromazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Triflupromazine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Triflupromazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Triflupromazine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Triflupromazine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Triflupromazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triflupromazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbinoxamine.
CarfentanilTriflupromazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triflupromazine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Triflupromazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carisoprodol.
CarteololTriflupromazine may increase the hypotensive activities of Carteolol.
CarvedilolTriflupromazine may increase the hypotensive activities of Carvedilol.
CeliprololTriflupromazine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Triflupromazine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Triflupromazine.
CetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triflupromazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorphenamine.
ChlorphentermineTriflupromazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Triflupromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triflupromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Triflupromazine.
CinchocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cinchocaine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Triflupromazine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Triflupromazine.
CitalopramThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Triflupromazine.
ClemastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Triflupromazine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Triflupromazine.
clomethiazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Triflupromazine.
ClomipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Triflupromazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Triflupromazine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Triflupromazine.
ClorazepateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clorazepate.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Triflupromazine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triflupromazine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Triflupromazine.
CocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cocaine.
CodeineTriflupromazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triflupromazine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Triflupromazine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Triflupromazine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Triflupromazine.
CyclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Triflupromazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Triflupromazine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Triflupromazine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Triflupromazine.
DantroleneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Triflupromazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.
DapoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine.
DapsoneThe serum concentration of Triflupromazine can be increased when it is combined with Dapsone.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Triflupromazine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Triflupromazine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Triflupromazine.
deramciclaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Triflupromazine.
DesloratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.
DetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine.
DextroamphetamineTriflupromazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Triflupromazine.
DextromoramideTriflupromazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triflupromazine.
DextropropoxypheneTriflupromazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triflupromazine.
DezocineTriflupromazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triflupromazine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Triflupromazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triflupromazine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Triflupromazine.
DifenoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Triflupromazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Triflupromazine.
DihydrocodeineTriflupromazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triflupromazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine.
DihydroetorphineTriflupromazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triflupromazine.
DihydromorphineTriflupromazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triflupromazine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Triflupromazine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Triflupromazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Diphenhydramine.
DiphenoxylateTriflupromazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triflupromazine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Triflupromazine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Triflupromazine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Triflupromazine.
DoramectinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Triflupromazine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Triflupromazine.
DoxycyclineThe serum concentration of Triflupromazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
DoxylamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doxylamine.
DPDPETriflupromazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triflupromazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Triflupromazine.
DrotebanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.
DyclonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Triflupromazine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Triflupromazine.
EfavirenzThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Triflupromazine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Triflupromazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triflupromazine.
EntacaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Triflupromazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Triflupromazine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Triflupromazine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Triflupromazine.
EscitalopramThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.
EsmololTriflupromazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Triflupromazine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Triflupromazine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Triflupromazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triflupromazine.
EthanolTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Triflupromazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Triflupromazine.
EthosuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl loflazepate.
EthylmorphineTriflupromazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triflupromazine.
EtidocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Triflupromazine.
EtorphineTriflupromazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triflupromazine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Triflupromazine.
EzogabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fenfluramine.
FentanylTriflupromazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triflupromazine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Triflupromazine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Triflupromazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Triflupromazine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Triflupromazine.
FlibanserinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Triflupromazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Triflupromazine.
GabapentinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Triflupromazine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Triflupromazine.
GlutethimideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Triflupromazine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Triflupromazine.
GuanfacineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halazepam.
HalofantrineThe serum concentration of Triflupromazine can be increased when it is combined with Halofantrine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Triflupromazine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triflupromazine.
HalothaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.
HeroinTriflupromazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triflupromazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hexobarbital.
HydrocodoneTriflupromazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triflupromazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Triflupromazine.
HydromorphoneTriflupromazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.
Hydroxyamphetamine hydrobromideTriflupromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Triflupromazine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Triflupromazine.
IloperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Triflupromazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Triflupromazine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Triflupromazine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Triflupromazine.
IndalpineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.
IndenololTriflupromazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Triflupromazine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Triflupromazine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Triflupromazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triflupromazine.
IsofluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Isoflurane.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Triflupromazine.
KetamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Triflupromazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triflupromazine.
KetobemidoneTriflupromazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triflupromazine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Triflupromazine.
LabetalolTriflupromazine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Triflupromazine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Triflupromazine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Triflupromazine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Triflupromazine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Triflupromazine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Triflupromazine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Triflupromazine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Triflupromazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Triflupromazine.
LevobunololTriflupromazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Triflupromazine.
Levomethadyl AcetateTriflupromazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triflupromazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomilnacipran.
LevorphanolTriflupromazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triflupromazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triflupromazine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Triflupromazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Triflupromazine.
LisdexamfetamineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Triflupromazine.
LithiumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lithium.
LofentanilTriflupromazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triflupromazine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Triflupromazine.
LoratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triflupromazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Triflupromazine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triflupromazine.
Lu AA21004The risk or severity of adverse effects can be increased when Triflupromazine is combined with Lu AA21004.
LumefantrineThe serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Triflupromazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Triflupromazine.
MeclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Medetomidine.
MefloquineThe serum concentration of Triflupromazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melperone.
MephentermineTriflupromazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.
MequitazineTriflupromazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.
MethadoneTriflupromazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.
Methadyl AcetateTriflupromazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triflupromazine.
MethamphetamineTriflupromazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triflupromazine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Triflupromazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine.
MetipranololTriflupromazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.
MetoprololTriflupromazine may increase the hypotensive activities of Metoprolol.
MetyrosineTriflupromazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Triflupromazine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Triflupromazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triflupromazine.
MilnacipranThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Triflupromazine.
MirtazapineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triflupromazine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Triflupromazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.
MolindoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Molindone.
MorphineTriflupromazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triflupromazine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Triflupromazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
NabiloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nabilone.
NadololTriflupromazine may increase the hypotensive activities of Nadolol.
NalbuphineTriflupromazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triflupromazine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Triflupromazine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Triflupromazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Triflupromazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Triflupromazine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Triflupromazine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Triflupromazine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Triflupromazine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Triflupromazine.
NitrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Triflupromazine.
NormethadoneTriflupromazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triflupromazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Triflupromazine.
OlanzapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Triflupromazine.
OndansetronThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ondansetron.
OpiumTriflupromazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triflupromazine.
OrphenadrineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Triflupromazine.
OsanetantThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Triflupromazine.
OxazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxazepam.
OxprenololTriflupromazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triflupromazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxybuprocaine.
OxycodoneTriflupromazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triflupromazine.
OxymorphoneTriflupromazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triflupromazine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Triflupromazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Triflupromazine.
ParaldehydeTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Triflupromazine.
ParoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.
PenbutololTriflupromazine may increase the hypotensive activities of Penbutolol.
PentazocineTriflupromazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triflupromazine.
PerampanelThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perphenazine.
PethidineTriflupromazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triflupromazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Triflupromazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triflupromazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenoxyethanol.
PhentermineTriflupromazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Triflupromazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triflupromazine.
PimozideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pimozide.
PindololTriflupromazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Triflupromazine.
PizotifenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Triflupromazine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Triflupromazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Triflupromazine.
PractololTriflupromazine may increase the hypotensive activities of Practolol.
PramipexoleTriflupromazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Triflupromazine.
PrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Triflupromazine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Triflupromazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triflupromazine.
PrilocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prilocaine.
PrimaquineThe serum concentration of Triflupromazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Triflupromazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Triflupromazine.
ProguanilThe serum concentration of Triflupromazine can be increased when it is combined with Proguanil.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Triflupromazine.
ProparacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propoxycaine.
PropranololTriflupromazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triflupromazine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Triflupromazine.
PSD502The risk or severity of adverse effects can be increased when Triflupromazine is combined with PSD502.
PyrimethamineThe serum concentration of Triflupromazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Triflupromazine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triflupromazine.
QuinacrineThe serum concentration of Triflupromazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Triflupromazine.
QuinidineThe serum concentration of Triflupromazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Triflupromazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Triflupromazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Triflupromazine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Triflupromazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.
RemifentanilTriflupromazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triflupromazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Triflupromazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triflupromazine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Triflupromazine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Triflupromazine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Triflupromazine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Triflupromazine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Triflupromazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Triflupromazine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Triflupromazine.
RomifidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Romifidine.
RopiniroleTriflupromazine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine.
RotigotineTriflupromazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triflupromazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Triflupromazine is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Triflupromazine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Triflupromazine.
ScopolamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Triflupromazine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Triflupromazine.
SertindoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Triflupromazine.
SinefunginThe serum concentration of Triflupromazine can be increased when it is combined with Sinefungin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Triflupromazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Triflupromazine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Triflupromazine.
SotalolTriflupromazine may increase the hypotensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Triflupromazine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Triflupromazine.
StiripentolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Stiripentol.
SufentanilTriflupromazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triflupromazine.
SulfadoxineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfametopyrazine.
SulpirideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Triflupromazine.
SuvorexantThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Triflupromazine.
tafenoquineThe serum concentration of Triflupromazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Triflupromazine.
TapentadolTriflupromazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triflupromazine.
TasimelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Triflupromazine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Triflupromazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Triflupromazine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Triflupromazine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triflupromazine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Triflupromazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine.
TetracaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrodotoxin.
ThalidomideTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Triflupromazine.
ThiamylalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Triflupromazine.
TiletamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiletamine.
TimololTriflupromazine may increase the hypotensive activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Triflupromazine.
TopiramateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Triflupromazine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Triflupromazine.
TramadolTriflupromazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triflupromazine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Triflupromazine.
TrazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trifluoperazine.
TrimethoprimThe serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Triflupromazine.
TriprolidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Triflupromazine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Triflupromazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triflupromazine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Triflupromazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Triflupromazine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Triflupromazine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Triflupromazine.
VigabatrinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Triflupromazine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Triflupromazine.
VortioxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Triflupromazine.
ZimelidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.
ZolazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Triflupromazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triflupromazine.
ZonisamideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cooper M, Wyllie JH: Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. [PubMed:497523 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23